Refine Search
Query Tree
Save query
A private query is only visible to you when you are logged-in and can not be used in RSS feeds
Results 1-4 of 4 for Criteria:ALLNAMES:(Matulis) Office(s):all Language:en Stemming: false
Filters
1
Page: / 1
Analysis
List Length
TitleCtrPubDate
Appl.NoApplicantInventorInt.Class
5-ARYL-4-(5-SUBSTITUTED 2,4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLES AS INHIBITORS OF HSP90 CHAPERONE AND THE INTERMEDIATES FOR PRODUCTION THEREOF
WO05.11.2009
PCT/LT2008/000003BIOTECHNOLOGIJOS INSTITUTASMATULIS, Daumantas
C07D 285/06
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
285
Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/-C07D283/183
01
Five-membered rings
02
Thiadiazoles; Hydrogenated thiadiazoles
04
not condensed with other rings
06
1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
Invention is related to novel compounds - 5-aryl-4-(5-substituted 2,4-dihydroxyphenyl)-1,2,3-thiadiazoles with general formula (I). The compounds can be used in biomedicine as active ingredients in pharmaceutical formulations, because they inhibit Hsp90 chaperone which participate in cancer progression. This invention is also related to new intermediate compounds which are used for the synthesis of thiadiazoles of general formula (I).

BENZIMIDAZO[1,2-C][1,2,3]THIADIAZOL-7-SULFONAMIDES AS INHIBITORS OF CARBONIC ANHYDRASE AND THE INTERMEDIATES FOR PRODUCTION THEREOF
EP06.05.2009
07793796BIOTECHNOLOGIJOS INSTMATULIS DAUMANTAS
C07D 513/04
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
513
Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/, C07D477/232
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
The invention is related to novel compounds - benzimidazo[1,2-c][1,2,3]thiadiazole sulfonamides, corresponding to the general formula (I). The compounds can be used in biomedicine as active ingredients in pharmaceutical formulations, because they inhibit enzymes which participate in disease progression such as glaucome. The compounds of formula (I) inhibits enzymes such as carbonic anhydrases and metallo proteinases. This invention is also related to new intermediate compounds which are used for the synthesis of sulfonamides of formula (I).

5-ARYL-4-(5-SUBSTITUTED 2,4-DIHYDROXYFENIL)-1,2,3-THIADIAZOLES AS INHIBITORS OF HSP90 CHAPERONE AND THE INTERMEDIATES FOR PRODUCTION THEREOF
LT25.11.2009
2008035BIOTECHNOLOGIJOS INSTMATULIS DAUMANTAS
C07D 285/00
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
285
Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/-C07D283/183
Ivention is related to novel compounds - 5-aryl-4-(5-substituted 2,4-dihydroxyphenyl)-1,2,3-thiadiazoles with general formula (I). The compounds can be used in biomedicine as active ingredients in pharmaceutical formulations, because they inhibit Hsp90 chaperone which participate in cancer progression. This invention is also related to new intermediate compounds which are used for the synthesis of thiadiazoles of formula (I).@

BENZIMIDAZO[1,2-C][1,2,3]THIADIAZOL-7-SULFONAMIDES AS INHIBITORS OF CARBONIC ANHYDRASE AND THE INTERMEDIATES FOR PRODUCTION THEREOF
EP06.05.2009
07793796BIOTECHNOLOGIJOS INSTMATULIS DAUMANTAS
C07D 513/04
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
513
Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/, C07D477/232
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
The invention is related to novel compounds - benzimidazo[1,2-c][1,2,3]thiadiazole sulfonamides, corresponding to the general formula (I). The compounds can be used in biomedicine as active ingredients in pharmaceutical formulations, because they inhibit enzymes which participate in disease progression such as glaucome. The compounds of formula (I) inhibits enzymes such as carbonic anhydrases and metallo proteinases. This invention is also related to new intermediate compounds which are used for the synthesis of sulfonamides of formula (I).

Results 1-4 of 4 for Criteria:ALLNAMES:(Matulis) Office(s):all Language:en Stemming: false
Filters
1
Page: / 1